Paul J. Hastings is the Chief Executive Officer of NKARTA INC., a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell immunotherapies for patients with cancer. With more than 25 years of experience in the biopharmaceutical industry, Hastings has established himself as a visionary leader skilled in advancing innovative therapies through clinical development, forging strategic partnerships, and scaling organizations for growth. His deep expertise in oncology and immunology has positioned NKARTA INC. to pioneer NK cell-based treatments targeting hematologic malignancies and solid tumors. Prior to joining NKARTA INC. in 2021, Hastings served as President and CEO of Zymeworks Inc., where he oversaw the progression of multiple bispecific antibody programs into clinical trials and secured a transformative $1.3 billion collaboration with Jazz Pharmaceuticals. Previously, at Seagen Inc. (formerly Seattle Genetics), he rose to Executive Vice President and Chief Business Officer, driving key alliances including the global agreement with Takeda for ADCETRIS (brentuximab vedotin), which generated billions in value. Earlier roles included Vice President of Business Development at Genentech, where he contributed to landmark oncology deals. Under Hastings' stewardship, NKARTA INC. has advanced its lead candidates, such as NKX101 for acute myeloid leukemia and NKX019 for B-cell non-Hodgkin lymphoma, with promising data from ongoing Phase 1 trials. His leadership emphasizes operational excellence, pipeline expansion, and innovative platforms like CAR-NK and multi-antigen targeting, aiming to deliver off-the-shelf therapies that address critical unmet needs in cancer treatment.